Premium
Marked efficacy of combined three‐drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome
Author(s) -
Morimoto M.,
Shimakawa S.,
Hashimoto T.,
Kitaoka T.,
Kyotani S.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12659
Subject(s) - dravet syndrome , topiramate , medicine , clobazam , anesthesia , antiepileptic drug , drug , valproic acid , anticonvulsant , pharmacology , pediatrics , epilepsy , psychiatry
Summary What is known and objective Dravet syndrome ( DS ) is an intractable epilepsy syndrome. The three‐drug combination therapy of sodium valproate ( VPA ), clobazam ( CLB ) and stiripentol ( STP ) is recommended worldwide. Case summary We present a case of DS , in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate ( TPM ) proved to be markedly effective. What is new and conclusion It is suggested that combination therapy with VPA , TPM and STP is for DS epilepsy.